Hiroaki Nagano
Papers
1
Total Citations
9
H-Index
1
About
Dr. Hiroaki Nagano is a leading figure in surgical oncology, with a primary research focus on the surgical management of pancreatic cancer and the advancement of minimally invasive techniques. His most notable contribution is spearheading the Japan Clinical Oncology Group study JCOG2202 (LAPAN study), a pivotal multi-institutional randomized phase III trial that directly compares minimally invasive distal pancreatectomy (MIDP) to open distal pancreatectomy for pancreatic cancer. This landmark 2024 study, which has already garnered significant attention with 9 citations, addresses the critical gap in evidence regarding the oncologic safety of laparoscopic and robotic approaches. Dr. Nagano’s work is instrumental in shaping global surgical standards, as he rigorously evaluates whether the short-term benefits of MIDP can be achieved without compromising long-term cancer outcomes. His research directly impacts clinical decision-making for surgeons and patients worldwide, providing the high-level evidence needed to validate or refine the adoption of these advanced techniques. Through this ambitious trial, Dr. Nagano is not only advancing the field of pancreatic surgery but also setting a new benchmark for evidence-based practice in surgical oncology.
Research Focus
Key Achievements
Top Papers
- 1